33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders

Clinical Evaluation & Classification of Dysphagia

Dysphagia—the subjective sensation of difficulty or obstruction during the passage of solids or liquids from the mouth to the stomach—is a high-yield clinical presentation in family medicine requiring rapid anatomical and functional localization.

Phases of Deglutition & Functional Anatomy

Deglutition comprises three coordinated phases:

1. Oral Phase (Voluntary): Food bolus is masticated, lubricated with saliva, and propelled backward by the tongue into the oropharynx (innervated by cranial nerves V, VII, and XII).
2. Pharyngeal Phase (Involuntary Reflex): Rapid neuromuscular reflex (<1 second) coordinated by the swallowing center in the medulla oblongata (nucleus ambiguus and solitary tract). Soft palate elevates to seal the nasopharynx; the larynx and hyoid bone pull superiorly and anteriorly, tilting the epiglottis downward to seal the laryngeal vestibule; vocal cords adduct; respiration temporarily ceases; and the upper esophageal sphincter (UES / cricopharyngeus) relaxes to allow bolus entry into the esophagus (cranial nerves IX, X, and XII).
3. Esophageal Phase (Involuntary): Coordinated primary and secondary peristaltic waves propel the bolus down the esophagus, while the lower esophageal sphincter (LES) relaxes via nitric oxide (NO) and vasoactive intestinal peptide (VIP) release to permit entry into the gastric fundus.

---\n

Oropharyngeal vs. Esophageal Dysphagia

The initial and most crucial clinical distinction is determining whether the swallowing difficulty is oropharyngeal or esophageal in origin:

[!CAUTION] Sensory Localization Fallacy in Esophageal Dysphagia: While food sticking localized to the lower retrosternal area reliably predicts a distal esophageal lesion, approximately 30% of patients with distal esophageal pathology (such as distal adenocarcinoma or lower esophageal rings) localize their sensation of sticking to the suprasternal notch. Therefore, a complaint of high cervical food sticking does not rule out distal esophageal disease and warrants thorough evaluation of the entire esophagus!

---\n

Esophageal Dysphagia: Mechanical Obstruction vs. Motility Disorders

Once esophageal dysphagia is established, the history reliably distinguishes mechanical luminal narrowing from neuromotor dysmotility:

                      ESOPHAGEAL DYSPHAGIA EVALUATION

                       Sensation of Food Sticking
                                   │
            ┌──────────────────────┴──────────────────────┐
            ▼                                             ▼
    SOLIDS ONLY INITIALLY                         SOLIDS AND LIQUIDS
    (Progressive over time)                       (Simultaneously from onset)
            │                                             │
            ▼                                             ▼
   MECHANICAL OBSTRUCTION                         MOTILITY DISORDER
   • Progressive: Malignancy, Stricture           • Intermittent: Spasm, Jackhammer
   • Intermittent: Schatzki Ring, EoE             • Progressive: Achalasia, Scleroderma
            │                                             │
            ▼                                             ▼
    INITIAL TEST: EGD                             INITIAL TEST: HIGH-RESOLUTION
    (Biopsy, dilate, visualize)                   ESOPHAGEAL MANOMETRY (HRM)

1. Mechanical Obstruction

• Pattern: Dysphagia begins strictly for solid foods (bread, meat, dense solids). Over weeks to months, as the mechanical lumen narrows beyond critical diameter (<13 mm), dysphagia progresses to soft foods and eventually to liquids.
• Progressive Mechanical Obstruction:
  • Esophageal Adenocarcinoma: Occurs in the distal third of the esophagus; linked to chronic gastroesophageal reflux disease (GERD), Barrett's esophagus (intestinal metaplasia with goblet cells), obesity, and tobacco. Manifests with rapid, relentless progression from solids to liquids accompanied by profound weight loss and iron deficiency anemia.
  • Esophageal Squamous Cell Carcinoma: Occurs predominantly in the proximal two-thirds (upper and middle) of the esophagus; strongly linked to chronic alcohol consumption, tobacco use, caustic ingestion, and achalasia.
  • Peptic Stricture: History of longstanding, severe heartburn and acid reflux that paradoxically improves as the stricture forms (the stricture acts as a physical barrier preventing acid reflux). Dysphagia progresses slowly over years without significant weight loss.
• Intermittent Mechanical Obstruction:
  • Schatzki Ring (Lower Esophageal Mucosal Ring): Concentric, smooth mucosal ring occurring precisely at the squamocolumnar junction (Z-line), almost always accompanied by a sliding hiatal hernia. Manifests with episodic, non-progressive dysphagia strictly to solids, classically presenting as acute meat bolus impaction ("steakhouse syndrome") when the patient eats hurriedly while consuming alcohol. Lumen caliber: >20 mm is asymptomatic; 13 to 20 mm causes intermittent symptoms; <13 mm causes constant solid food dysphagia.

2. Esophageal Motility Disorders

• Pattern: Dysphagia occurs for both solids and liquids simultaneously from disease onset.
• Achalasia: Progressive solid and liquid dysphagia accompanied by regurgitation of bland, undigested food, nocturnal coughing, and weight loss.
• Distal (Diffuse) Esophageal Spasm (DES): Episodic, intermittent solid and liquid dysphagia triggered by hot or cold beverages and emotional stress, accompanied by severe, squeezing retrosternal chest pain that mimics acute myocardial infarction. Barium swallow displays a non-propulsive "corkscrew" or "rosary bead" esophagus.
• Systemic Sclerosis (Scleroderma Esophagus): Smooth muscle atrophy and extensive fibrous replacement of the muscularis propria in the distal two-thirds of the esophagus. Produces profound hypotensive lower esophageal sphincter (LES) and complete aperistalsis, resulting in devastating gastroesophageal reflux, severe erosive esophagitis, Barrett's esophagus, and peptic strictures.

---\n

Achalasia: Pathophysiology, Diagnosis & Management

Achalasia is the most well-characterized primary esophageal motility disorder, defined by failure of the lower esophageal sphincter (LES) to relax upon swallowing and complete absence of organized peristalsis in the esophageal body.

Pathophysiology

• Characterized by inflammatory, immune-mediated degeneration and loss of inhibitory postganglionic ganglion cells in the myenteric (Auerbach) plexus of the distal esophagus.
• The selective loss of neurons containing nitric oxide synthase (NOS) and vasoactive intestinal peptide (VIP) unmasks unopposed cholinergic stimulation (acetylcholine and substance P), resulting in failure of LES relaxation and elevated baseline basal LES tone.
• Secondary achalasia (Pseudoachalasia) can closely mimic primary achalasia; it is caused by tumor infiltration at the gastroesophageal junction (most commonly gastric cardia adenocarcinoma) or by Trypanosoma cruzi infection (Chagas disease, which also causes megacolon and dilated cardiomyopathy).

Diagnostic Evaluation

1. High-Resolution Esophageal Manometry (HRM): The gold standard diagnostic modality (Chicago Classification v4.0). Required diagnostic criteria:
   • Incomplete LES Relaxation: Elevated Integrated Relaxation Pressure (IRP; typically >15 mmHg depending on manometry system);
   • Complete Aperistalsis: 100% failed peristaltic contractions in the esophageal body.
2. Barium Esophagram (Timed Barium Swallow): Demonstrates dilated esophageal body with retained barium column, air-fluid level, absent peristaltic stripping waves, and smooth, symmetric distal tapering resembling a "bird's beak" or "pencil tip".
3. Upper Endoscopy (EGD): Mandatory in all patients to definitively rule out pseudoachalasia (malignancy). Endoscopy reveals dilated esophagus with retained food residue; the gastroesophageal junction is tightly closed but easily "pops" open with gentle endoscope advancement (in contrast to malignancy, which resists passage).

Therapeutic Modalities

Treatment aims to reduce LES resting pressure to facilitate gravity-assisted esophageal emptying:

• Laparoscopic Heller Myotomy with Partial Fundoplication (Dor or Toupet): Surgical division of the circular muscle fibers of the LES; addition of a partial 180-to-270-degree anterior or posterior fundoplication prevents severe postoperative acid reflux.
• Peroral Endoscopic Myotomy (POEM): Advanced endoscopic technique creating a submucosal tunnel to perform myotomy of the inner circular muscle; provides exceptional relief of dysphagia with minimal invasiveness, though long-term PPI therapy is frequently required for post-procedure reflux.
• Pneumatic Balloon Dilation: Graded endoscopic dilation utilizing large pneumatic balloons (30, 35, 40 mm) to tear circular LES muscle fibers. High efficacy, but carries a 1% to 3% risk of esophageal perforation.
• Botulinum Toxin Injection: Endoscopic injection of botulinum toxin A (inhibits presynaptic acetylcholine release) into the LES. Highly effective short-term, but benefits wane within 6 to 12 months; strictly reserved for elderly, frail patients who are poor candidates for definitive surgical or pneumatic procedures.

---\n

Acute Infectious Esophagitis in Immunocompromised Hosts

Infectious esophagitis presents with acute-onset severe odynophagia (painful swallowing), retrosternal chest pain, and dysphagia, occurring predominantly in patients with advanced HIV/AIDS, solid organ or bone marrow transplants, hematologic malignancies, or prolonged systemic corticosteroid therapy.

Comparison of Infectious Esophagitis Pathogens

[!IMPORTANT] Biopsy Location Board Rule for Viral Esophagitis:

• For CMV, take biopsies from the ulcer BASE, because CMV infects vascular endothelial and mesenchymal stromal cells located in the granulation tissue of the ulcer bed.
• For HSV, take biopsies from the ulcer MARGIN / EDGE, because HSV is a dermotropic virus that infects viable squamous epithelial cells at the periphery of the ulceration.

---\n

Pill-Induced (Caustic / Drug-Induced) Esophagitis

Pill-induced esophagitis is an acute focal esophageal mucosal injury caused by direct caustic chemical contact and localized hyperosmolar or acidic toxicity when an orally ingested medication remains in prolonged contact with the esophageal wall.

Culprit Medications & Chemical Mechanisms

• Antibiotics: Doxycycline and Tetracycline hydrochloride (produce an extremely acidic solution with pH <3.0 when dissolved, inducing chemical mucosal coagulative necrosis); Clindamycin.
• Bisphosphonates: Alendronate, risedronate (induces severe epithelial cell toxicity and focal deep ulceration).
• Electrolytes: Potassium chloride (KCl) tablets (hyperosmolar erosion and direct cellular lysis).
• Anti-Inflammatory Drugs: Aspirin and non-selective NSAIDs (direct topical cytotoxicity and inhibition of local mucosal prostaglandins).
• Iron Supplements: Ferrous sulfate (direct mucosal oxidation and free radical generation, producing brown-black mucosal tattooing).
• Cardiovascular: Quinidine, mexiletine.

Anatomic Localization & Risk Factors

• Occurs classically at points of physiologic anatomical narrowing where transit is naturally delayed: most commonly in the mid-esophagus where the aortic arch and left mainstem bronchus cross the esophageal lumen, or at the level of the lower esophageal sphincter.
• Precipitating Behaviors: Ingestion of tablets without water ("dry-swallowing") or with insufficient fluid (<1-2 ounces), and immediately retiring to bed or lying supine post-ingestion. Decreased salivary flow and absence of gravity during sleep cause the tablet to adhere to mid-esophageal squamous mucosa.

Clinical Presentation & Management

• Presentation: Sudden onset of sharp, severe retrosternal chest pain and intense odynophagia developing hours after taking a medication at bedtime. Symptoms are so severe that patients refuse to swallow saliva.
• Endoscopy: Reveals localized, discrete, circumscribed mucosal ulceration with normal surrounding mucosa, frequently with "kissing ulcers" on opposing mucosal walls.
• Prevention & Patient Education:
  1. Take all pills with a full 8-ounce (240 mL) glass of water;
  2. Remain completely upright (sitting or standing) for at least 30 minutes after ingestion;
  3. Never swallow medications immediately prior to going to sleep;
  4. Switch to liquid oral formulations for patients with underlying esophageal dysmotility or strictures.
• Treatment: Immediate discontinuation of the offending agent; supportive care with liquid sucralfate slurries (1 g PO QID) and proton pump inhibitors for 1 to 2 weeks.

---\n

Eosinophilic Esophagitis (EoE)

Eosinophilic esophagitis is a chronic, immune- and antigen-mediated inflammatory esophageal disease characterized clinically by symptoms of esophageal dysfunction and histologically by eosinophil-predominant inflammation.

Epidemiology & Immunopathogenesis

• Demographics: Predominantly affects young males (aged 20 to 40 years), with a male-to-female ratio of 3:1.
• Atopic Triad: Up to 70% to 80% have a personal or family history of atopic conditions: allergic rhinitis, asthma, atopic dermatitis (eczema), or IgE-mediated food allergies.
• Pathophysiology: Allergen-driven Th2-mediated allergic response. Food antigens penetrate a defective epithelial mucosal barrier, activating Th2 helper cells to secrete IL-4, IL-5, and IL-13. IL-13 stimulates esophageal epithelial cells to produce eotaxin-3 (CCL26), a potent chemokine that drives selective eosinophil migration, tissue infiltration, and degranulation. Prolonged eosinophil activation releases major basic protein and transforming growth factor-beta (TGF-β), driving subepithelial fibrosis, lamina propria remodeling, and fibrostenotic stricture formation.

Clinical Presentation & Endoscopic Findings

• Presentation: Recurrent, intermittent dysphagia strictly to solid foods; repetitive, prolonged chewing and slow eating habits ("last person to finish a meal"); compensatory fluid consumption to wash down food boluses; and acute esophageal food bolus impaction ("steakhouse syndrome") requiring emergency endoscopic disimpaction.
• Endoscopic Diagnostic Findings:
  • Stacked circular rings ("trachealization" or "feline esophagus");
  • Longitudinal linear furrows parallel to the long axis of the esophagus;
  • Whitish punctate exudates or papules (representing dense microabscesses of eosinophils);
  • Mucosal friability and fragility ("crepe paper" mucosa), which tears easily upon gentle endoscope passage;
  • Narrow-caliber esophagus and distal fibrostenotic strictures.

Diagnostic Criteria (Updated Consensus Guidelines)

Diagnosis requires all three of the following criteria:

1. Symptoms of esophageal dysfunction (dysphagia, food impaction);
2. Esophageal biopsy demonstrating ≥15 eosinophils per high-power field (HPF) (~60 eosinophils/mm²) in at least one mucosal specimen;
3. Exclusion of non-EoE disorders that cause esophageal eosinophilia (GERD, eosinophilic gastroenteritis, Crohn disease, achalasia, infection).

Stepwise Management of EoE

Therapy aims to achieve both symptomatic relief and histologic remission (<15 eosinophils/HPF) to prevent irreversible transmural remodeling and strictures:

1. Proton Pump Inhibitors (First-Line Pharmacotherapy):
   • High-dose PPI (e.g., Omeprazole 20 to 40 mg BID or Pantoprazole 40 mg BID) for 8 to 12 weeks.
   • Dual Mechanism: In addition to acid suppression, PPIs exert direct anti-inflammatory effects by inhibiting Th2-stimulated eotaxin-3 expression in esophageal epithelial cells independent of gastric pH.
   • Achieves histologic remission in 30% to 50% of patients (formerly termed PPI-responsive esophageal eosinophilia).
2. Topical Swallowed Corticosteroids (First-Line Pharmacotherapy):
   • Topical corticosteroids deliver direct mucosal anti-inflammatory action with minimal systemic absorption:
     • Swallowed Fluticasone Propionate: 440 to 880 mcg twice daily. Administered via a metered-dose inhaler sprayed directly into the oral cavity and swallowed without a spacer, without inhaling.
     • Swallowed Budesonide Viscous Suspension: 1 to 2 mg twice daily. Oral respule mixed with sucralose (Splenda; 5 packets per 1 mg) or honey to form a thick, viscous slurry that coats the esophageal wall.
   • Crucial Patient Education: Patients must rinse their mouth with water and spit (without swallowing) after administration to prevent oral candidiasis, and must remain NPO (no eating or drinking) for at least 30 to 60 minutes after dosing.
3. Dietary Elimination Therapy:
   • Empiric Six-Food Elimination Diet (SFED): Eliminates the six most common food allergen triggers: cow's milk, wheat/gluten, egg, soy, peanuts/tree nuts, and fish/shellfish for 6 to 8 weeks, followed by sequential food reintroduction with surveillance endoscopies. Achieves >70% remission.
   • Step-Up 2-4-6 Approach: Starts with eliminating the two most common culprits (milk and wheat), escalating to 4 and 6 foods only if remission is not achieved.
4. Targeted Biologic Therapy (Dupilumab):
   • Dupilumab (Dupixent): Fully human monoclonal antibody directed against the interleukin-4 receptor alpha (IL-4Rα) subunit, inhibiting both IL-4 and IL-13 signaling cascades.
   • Dosing: 300 mg administered subcutaneously once weekly.
   • Indications: FDA-approved for adults and pediatric patients aged ≥1 year weighing ≥15 kg with refractory EoE, severe recurrent strictures, or intolerance to topical therapies.
5. Endoscopic Balloon Dilation:
   • Indicated for dominant fibrostenotic strictures causing persistent solid food dysphagia despite anti-inflammatory therapy. Must be performed gently and conservatively with gradual balloon sizing due to increased risk of deep mucosal tears and esophageal perforation.